CELLIVITY is available to adults only. Supplement pages are general product information; peptide records are not a sales offer and are not for human use.
Age confirmation is a declaration, not identity verification. Restricted research access still requires separate professional eligibility checks.Privacy and legal notice ↗
Bremelanotide, historically called PT-141, is a cyclic peptide melanocortin-receptor agonist. An authorised finished medicine exists in some markets for a narrow indication, but a bulk or catalogue vial is not equivalent to that finished product.
Research focus
Melanocortin-receptor pharmacology in defined clinical and research settings.
Current evidence context
Clinical evidence and approval apply to a specific formulation, indication and population. They do not validate general performance, longevity claims or independently sourced material.
Questions this record follows
Which receptor subtypes drive measured physiological responses?
How do authorised formulation and exposure relate to benefit and adverse effects?
Which safety signals require monitoring in defined clinical populations?
Follow the sources
Registry entries identify reference substances. Literature links describe research and do not certify this product or its batch.
Exact CELLIVITY-batch review is pending. Reference files below describe their own declared samples.
Purity, identity, per-vial content and sterility are separate results.
Product
PT-141 / Bremelanotide
Record
CEL-P-PT1-001
Files received
0
0 FILES
No product-specific laboratory file has been uploaded yet.
AVAILABILITY
Tell us what your lab needs.
Request current availability for a lawful institutional, analytical or laboratory purpose. We confirm the exact presentation, price, batch and document state before any next step.
Exact presentation review
Jurisdiction and purpose check
Batch-document confirmation
No medical or human-use guidance
SELECTED PRODUCTPT-141 / BremelanotideCEL-P-PT1-001 · response after manual review
PT-141 / Bremelanotide: before you enquire
What exactly does the selected format mean?＋
The mg or IU value is the declared material content per vial; it is not the container volume. Your selected presentation and quantity are saved with your enquiry. The final price is confirmed in the response.
Which batch will be supplied?＋
The specific batch and its documents are confirmed in the response. Files shown here may be supplier reference samples; the current record does not yet contain a qualified CELLIVITY lot dossier.
When can it arrive in Thailand?＋
For confirmed local stock, the planned window is 2–3 working days in Thailand. Pattaya timing is agreed directly. Incoming or specially sourced products have a separate estimate, confirmed before a commitment.
Can I enquire about several products together?＋
Yes. Add each format and quantity to the cart, then send one availability enquiry. Your selected items are kept together for review.
CELLIVITY
PT-141 / Bremelanotide
CEL-P-PT1-001 · 10 mg
Bremelanotide, historically called PT-141, is a cyclic peptide melanocortin-receptor agonist. An authorised finished medicine exists in some markets for a narrow indication, but a bulk or catalogue vial is not equivalent to that finished product.
Melanocortin-receptor pharmacology in defined clinical and research settings.
Other names
PT-141 · bremelanotide
PubChem CID
9941379
CAS number
189691-06-3
Molecular formula
C50H68N14O10
Molecular weight
1025.2 g/mol
Peptide length
7 amino acids
Compound class
Synthetic cyclic melanocortin-receptor agonist
Follow the sources
Clinical evidence and approval apply to a specific formulation, indication and population. They do not validate general performance, longevity claims or independently sourced material.
Which receptor subtypes drive measured physiological responses?
How do authorised formulation and exposure relate to benefit and adverse effects?
Which safety signals require monitoring in defined clinical populations?
Lab documents
CELLIVITY lot review pending
No lab files received
A narrow authorised medical use cannot be extended to other populations, claims, routes or catalogue formulations.
